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2ABSTRACT
Peroxisomes are organelles that function in the b-oxidation of very-long and
long-chain acyl-CoAs, bile acid-CoA intermediates, prostaglandins,
leukotrienes, thromboxanes, dicarboxylic fatty acids, pristanic acid and
xenobiotic carboxylic acids. The very long- and long-chain acyl-CoAs are
mainly chain-shortened and then transported to mitochondria for further
metabolism. We have now identified and characterized two peroxisomal acyl-
CoA thioesterases, named PTE-Ia and PTE-Ic, which hydrolyze acyl-CoAs to
the free fatty acid and coenzyme A. PTE-Ia and PTE-Ic show 82% sequence
identity at amino acid level and a putative peroxisomal type 1 targeting signal
of –AKL was identified at the carboxy-terminal end of both proteins.
Localization experiments using green fluorescent fusion protein showed PTE-
Ia and PTE-Ic to be localized in peroxisomes. Despite their high level of
sequence identity, we show that PTE-Ia is mainly active on long-chain acyl-
CoAs, while PTE-Ic is mainly active on medium-chain acyl-CoAs. Lack of
regulation of enzyme activity by free CoASH suggests that PTE-Ia and PTE-Ic
regulate intra-peroxisomal levels of acyl-CoA, and they may have a function
in termination of b-oxidation of fatty acids of different chain-lengths. Tissue
expression studies revealed that PTE-Ia is highly expressed in kidney, while
PTE-Ic is most highly expressed in spleen, brain, testis and proximal and
distal intestine. Both PTE-Ia and PTE-Ic were highly upregulated in mouse
liver by treatment with the peroxisome proliferator WY-14,643 and by fasting,
in a peroxisome proliferator-activated receptor alpha (PPARa) dependent
manner. These data show that PTE-Ia and PTE-Ic have different functions
based on different substrate specificities and tissue expression.
Abbreviations: PTE-Ia, peroxisomal acyl-CoA thioesterase Ia; PTE-Ic,
peroxisomal acyl-CoA thioesterase Ic; CoASH, coenzyme A; PPARa ,
peroxisome proliferator-activated receptor alpha; BSA, bovine serum
albumin; PTE-2, peroxisomal acyl-CoA thioesterase 2; GFP, green fluorescent
protein; PTS1, peroxisomal type-1 targeting signal; ORF, open reading frame.
3INTRODUCTION
Peroxisomes are organelles present in most eukaryotic cells and play a key
role in the metabolism of a variety of lipids such as very long-chain fatty
acids, dicarboxylic fatty acids, bile acids, prostaglandins, leukotrienes,
thromboxanes, pristanic acid and xenobiotic fatty acids, and in the
biosynthesis of ether-linked glycerolipids such as plasmalogens and structural
ether lipids abundant in the central nervous system (for reviews, see (1,2)).
Peroxisomal b-oxidation of very long- and long-chain CoA esters results in
chain-shortening of fatty acids which may then be transported to the
mitochondria as carnitine esters for further oxidation. b-Oxidation of other
types of lipids such as prostanoids leads to chain-shortening in the
peroxisome for excretion as free carboxylic acids in the urine (3). Almost 30
years ago a group of compounds were identified which were shown to cause
peroxisome proliferation in rodents, hence they were named peroxisome
proliferators. Peroxisome proliferators are a structurally diverse group of
compounds including plastisizers, hypolipidemic drugs (for example
clofibrate), and WY-14,643. Peroxisome proliferators induce the expression of
several genes involved in degradation of fatty acids, and cause peroxisome
proliferation, hepatomegaly and hepatocarcinogenesis in rodent liver (4).
These effects are mediated via the peroxisome proliferator-activated receptor
alpha (PPARa), which was shown to be a nuclear receptor in control of lipid
metabolism (5,6). PPARa induces the expression of many genes involved in
peroxisomal and mitochondrial b-oxidation and w-oxidation of fatty acids,
and targeted disruption of this receptor in mouse has established its key role
as a mediator of lipid metabolism (6). Free fatty acids were identified as
physiological, endogenous ligands for the PPARa (7-10), which probably
mediates the effects of PPARa during fasting (11-14).
One group of enzymes which were previously identified to be responsive to
treatment by peroxisome proliferators were the acyl-CoA thioesterases (for
review see (15)). These enzymes are found in various compartments in the cell
including cytosol, mitochondria, microsomes and peroxisomes. Acyl-CoA
thioesterases catalyze the hydrolysis of acyl-CoAs to the free fatty acid and
coenzyme A, thereby regulating intracellular content of various acyl-CoAs,
4free fatty acids and free CoASH. The acyl-CoA thioesterase activity in
peroxisomes was characterized and activity was identified with acyl-CoA
esters from C2- to C20-CoA, with highest activity detected for medium- and
long-chain acyl-CoAs (16). Since then, several peroxisomal acyl-CoA
thioesterases have been cloned and characterized. A family of acyl-CoA
thioesterases was identified in mouse, named Type-I acyl-CoA thioesterases,
which at the time was shown to contain four highly homologous genes, two
peroxisomal (PTE-Ia and -Ib), one mitochondrial (MTE-I), and one cytosolic
(CTE-I), all of which are located in a cluster on mouse chromosome 12 (17). In
human, four Type-I acyl-CoA thioesterases have been identified, with
putative localizations in cytosol, mitochondria and peroxisomes (17,18).
Another peroxisomal acyl-CoA thioesterase called PTE-2, which is unrelated
to the Type-I gene family above, was identified as the major acyl-CoA
thioesterase in mouse liver peroxisomes (19), with homologues in human,
yeast and plants (20-23). This is a broad range acyl-CoA thioesterase that
hydrolyzes almost all acyl-CoAs present in peroxisomes, including bile acid-
CoA esters, short-, medium- and long-chain acyl-CoAs and intermediates
from b-oxidation of pristanoyl-CoA. It is hypothesized that this enzyme is
important in regulating intracellular levels of acyl-CoAs and CoASH during
times of high b-oxidation and fatty acid overload.
In this study, we have cloned and characterized PTE-Ia and PTE-Ic, the latter
which is a newly identified member of the Type-I family of acyl-CoA
thioesterases. Both these enzymes are peroxisomal, are highly homologous
(>80% sequence identity at amino acid level), and hydrolyze long-chain and
medium-chain acyl-CoAs respectively. These enzymes may play a role in
controlling acyl-CoA levels within the peroxisome in different tissues.
EXPERIMENTAL PROCEDURES
Chemicals- All commercially available acyl-CoAs used in this study were from
Sigma (St. Louis, MO). Behenoyl-CoA, lignoceryl-CoA, cerotoyl-CoA and
dimethylnonanoyl-CoA were kind gifts from Dr. Ronald Wanders.
Animals and treatments- All tissues used in this study were excised from adult
male wild-type and PPARa-null mice on a pure Sv/129 genetic background
5(kindly provided by Dr. Frank Gonzalez and Dr. Jeffrey Peters). The mice
were fed a standard chow diet (R36, Lactamin, Vadstena, Sweden) or
alternatively fed a diet containing 0.1% WY-14,643 (Calbiochem-
Novabiochem International) or fasted for 24 hours. Animals were sacrificed
by CO2 asphyxiation followed by cervical dislocation and tissues were excised
and stored at –70oC for preparation of total RNA.
cDNA Cloning and Expression- The putative open reading frames for PTE-Ia
(17) and PTE-Ic were derived from genomic databases and expressed
sequence tags (ESTs) from the mouse EST database (www.ncbi.nlm.nih.gov),
respectively, and were amplified using the following primers: for PTE-Ia: 5’-
C A T A T G A T G T T T T C T G T A T A A T C A C T C C - 3 ’  a n d  5 ’ -
CATATGCACGCATTTACCAC-3’ (which amplifies a splice variant named
PTE-Ia 5’ :1 – see below), and for PTE-Ic using: 5’-
C A T A T G T G T C A C T A C T C A A A G A A A A T C A T – 3 ’  a n d  5 ’ -
CATATGGTGCCAACAGTAAGCCT-3’ (Cybergene AB, Huddinge, Sweden),
with the addition of an Nde I site (indicated in bold). The full-length open
reading frames were amplified by reversed transcriptase-PCR (RT-PCR) using
a template of WY-treated mouse liver total RNA. RT-PCR was performed
using the One Step RNA PCR Kit (avian myeloblastosis virus (AMV)) (Takara
Biomedicals). Thermal cycling for PTE-Ia was performed for 40 cycles at 94oC
for 30 sec, 59oC for 30 sec, and 72oC for 2.5 min, followed by 72oC for 10 min.
For PTE-Ic an annealing temperature of 55oC, 4 min extension and 35 cycles
was used. The open reading frames were cloned into the Nde I site of the pET-
16b plasmid (Novagen Inc.) and fully sequenced. For expression of PTE-Ia
and PTE-Ic in BL21(DES3)pLysS cells, bacteria were cultured in 1 liter of
Luria-Bertani medium at 37oC until an A600 nm of about 0.6 was reached.
Induction of protein expression for PTE-Ia was performed by addition of 1
mM isopropyl-1-thio-b-D-galactopyranoside (IPTG), and growth was
continued for 3 h. PTE-Ic was induced with 0.2 mM IPTG and growth was
continued for 15 h at 18oC. The bacteria were collected and frozen at –20oC.
Bacterial pellets for PTE-Ia and PTE-Ic were thawed and resuspended in
BugBuster‰ Protein Extraction Reagent (Novagen Inc.) with addition of
Benzonase (Novagen Inc.), incubated for 20 min at room temperature and
centrifuged at 16,000 ¥ g for 20 min at 4oC.  The supernatants were then used
6for purification on a Hi-Trap‰  column (Amersham Biosciences, Inc.).
Following equilibration of the column, the supernatant was applied, and the
column was washed stepwise with 50, 100, 200, and 300 mM imidazole in 20
mM phosphate, 0.1 M sodium chloride to remove contaminating proteins. The
PTE-Ia protein was eluted in the 500 mM imidazole fraction and PTE-Ic in the
300 mM imidazole fraction. These fractions were subsequently used for acyl-
CoA thioesterase activity measurements.
Determination of Acyl-CoA Thioesterase Activity- Acyl-CoA thioesterase activity
was measured spectrophotometrically at 412 nm with 5,5’-dithiobis (2-
nitrobenzoic acid) (DTNB) (19). Since PTE-Ia thioesterase activity was
inhibited at substrate concentrations higher than 5-10 mM with acyl-CoAs
between C14-C20, bovine serum albumin (BSA) was added at a molar ratio of
BSA/acyl-CoA of 1:4.5. Enzyme activities were measured in three different
recombinant protein preparations of PTE-Ia and in two recombinant protein
preparations of PTE-Ic. The protein concentration was determined using the
Bradford assay (24). The effect of CoASH on the enzyme activity was
measured at 232 nm in phosphate buffered saline. The enzyme kinetics were
calculated using Sigma Plot enzyme kinetics program.
Expression of PTE-Ia 5’-splice Variants: Since analysis of mouse expressed
sequence tags (ESTs) indicated the existence of two different 5’-splice variants
for PTE-Ia, these were examined in liver and kidney under normal conditions
and during fasting using RT-PCR. The two splice variants were amplified
using the following primers: PTE-Ia 5’:1 5’-GACTTTTGTAGCGGTATCTT-3’
(located at position 539-559 of cDNA sequence for 5’:1 submitted to Genbank)
and PTE-Ia 5’:2 - 5’ TTAGCTCTTGACCTTGTCTGTCTGC-3’ (located at
position 11-35 of cDNA sequence for 5’:2 submitted to Genbank), together
with a common primer 5’-CAGGTGGATAATGTCCATGTCCTTA-3’ (located
at position 1383-1407 of cDNA for 5’:1 and 640-664 of cDNA for 5’:2). The 5’:1
splice variant was amplified by RT-PCR using an annealing temperature of
53oC for 1 min and 35 cycles, while for the 5’:2 splice variant, 57oC for 35
cycles was used.
7Localization of PTE-Ia and PTE-Ic using Green Fluorescent Fusion Protein and Cell
Transfection Experiments- Oligonucleotides were designed based on the
sequence of the open reading frames of PTE-Ia (5’:1) and PTE-Ic for cloning as
a fusion proteins with green fluorescent protein (GFP), to examine targeting
of the proteins. The open reading frame of PTE-Ia (5’:1) and PTE-Ic were
amplified by RT-PCR, using the same primers used for cloning into the
pET16b plasmid. Both PCR products were cloned into the pcDNA3.1/NT-
GFP vector (Invitrogen) in frame with the GFP at the amino-terminal end.
Sequence analysis was performed on the cloned products. In addition, two
carboxy-terminal GFP constructs, one full-length construct, and one construct
lacking the first 11 amino acids of PTE-Ia were cloned. These constructs were
amplified using the following primers 5’-AGGATGCACGCATTTACCAC-3’
(5’ :1) ,  5’-AGGATGGCACCTACTGTGAT-3’ (5’ :2)   and 5’-
GTTTTGCTGGGATTGTCT-3’ (common primer) and cloned into the
pcDNA3.1/CT-GFP vector (Invitrogen) as described above.
Human skin fibroblasts from a control subject and a Zellweger patient were
grown as described previously (19). Both control and Zellweger cells were
grown overnight in 60-mm dishes on glass coverslips and were transfected
with 10 m g of PTE-Ia/GFP or PTE-Ic/GFP plasmid using the calcium
phosphate method. Transfected cells were grown for 48 h and cells were fixed
and prepared for immunoflourescence microscopy as described in (19). The
cells were examined in Leica DM IRBE fluorescence microscope, using
Hamamatsu C4742-95 Twain interface software.
Tissue Expression and Regulation by WY-14,643 and Fasting by RT-PCR- The
tissue expression of PTE-Ia and PTE-Ic was examined in liver, kidney, heart,
lung, adrenal, spleen, testis, muscle, brain, brown adipose tissue, white
adipose tissue, proximal intestine, distal intestine, and gallbladder. The
regulation by WY-14,643 was investigated in WY-treated livers from wild-
type (+/+) and PPARa-null (-/-) mice. Regulation by fasting was examined in
liver, kidney and heart from wild-type and PPARa-null mice. PTE-Ia was
amplified using the following primers: 5’- TGGATGGCAAAAAGAAGACA-
3’ and 5’-GGGTGCCCAAGGAGGTCA-3’ (representing a fragment of 505 bp
from 2021-2525 of the 5’:1 cDNA sequence submitted to Genbank, which will
8amplify both variants 5’:1 and 5’2 of PTE-Ia), and PTE-Ic using 5’-
T A A T C A A T G G C G C C A C G G T C A A - 3 ’  a n d  5 ’ -
CCAGCTATGTCACTACTCAAAGAA-3’ (representing a 534 bp fragment
from 900 – 1434 of the cDNA sequence). RT-PCR for PTE-Ia was performed
for 35 cycles of 94oC for 30 sec, 48oC for 30 sec, and 72oC for 3 min, followed
by 72oC for 10 min. For PTE-Ic, an annealing temperature of 54oC and
extension time of 2 min was used. A fragment of b-actin was amplified as a
c o n t r o l ,  u s i n g  t h e  f o l l o w i n g  p r i m e r s  5 ' -
A T G G A T G A C G A T A T C G C T G C G C T G G - 3 ’  a n d  5 ’ -
GGTCATCTTTTCACGGTTGGCCTTAGGGT-3’ and thermal cycling was
performed for 28 cycles with an annealing temperature of 65oC, and extension
of 30 sec.
Western Blot Analysis of Tissue Expression and Regulation by WY-14,643 and
Fasting- Tissue expression of PTE-Ia at protein level was examined in muscle,
heart, lung, brown adipose tissue, brain, liver and kidney from Sv/129 male
mice. The regulation of expression by WY-14,643 and fasting was investigated
in wild-type and PPARa-null mice. Tissue pieces (about 0.1 g in 200 ml buffer)
were homogenized in 50 mM potassium phosphate buffer, pH 7.0. Fifty
micrograms of protein was analyzed by Western blot as described (14), using
an anti-rabbit PTE-Ia antibody (Sigma Genosys) generated against the first 15
amino acids of the protein, resulting in an antibody that specifically
recognizes the long variant of PTE-Ia (5’:1).
RESULTS
cDNA Cloning and Sequence Analysis- We previously identified and cloned a
novel gene family of four type-I acyl-CoA thioesterases, with members
identified in cytosol (CTE-I), mitochondria (MTE-I) and peroxisomes (PTE-Ia
and PTE-Ib) (17).  These genes are localized in a cluster on chromosome 12 in
mouse. Recent EST database searches have identified two further putative
peroxisomal Type-I acyl-CoA thioesterases, namely PTE-Ic and PTE-Id, which
are also located in the same cluster on mouse chromosome 12 (Fig. 1). Of the
four putative peroxisomal genes identified in mouse, PTE-Ia and PTE-Ic show
highest homology to each other, and were therefore cloned and characterized
9together in this study. The genomic organization for PTE-Ia and PTE-Ic were
obtained from the mouse genomic database (ENSEMBL, www.ensembl.org),
as outlined in Fig. 2A. Both proteins are encoded by 3 exons, spaced by 2
introns. Analysis of EST sequences for PTE-Ia suggested the possible existence
of an additional small exon (30-37 bp) further upstream in the 5’-end, which
results in two different splice variants depicted as 5’:1 and 5’:2 in Fig. 2A.  The
existence of these two splice variants was further supported by sequence
analysis, since the exon-intron boundaries are consistent with the donor-
acceptor splice rules, as shown in Fig. 2B. Furthermore, these two splice
variants were amplified by RT-PCR from liver and kidney (see below).
Based on the genomic sequences, the corresponding ORFs were amplified by
RT-PCR and fully sequenced. The full-length cDNAs were assembled based
on ESTs corresponding to the 5’ and 3’ untranslated regions (UTRs) and
verified by analysis of mouse genomic sequences. Sequence analysis of the
gene products for PTE-Ia and PTE-Ic show a sequence identity of 82% at
amino acid level in their open reading frames (Fig. 3). The cDNAs isolated for
PTE-Ia and PTE-Ic encode proteins of 432 and 421 amino acids, with
calculated molecular masses of 47.4 kDa and 46.6 kDa respectively.
Interestingly, the PTE-Ia cDNA of the PTE-Ia 5’:1 splice variant contains an
extra 11 amino acids in the amino-terminal end, while the 5’:2 splice variant
splices out the first methionine, with the protein starting at the second
methionine, similar to the cytosolic and the other peroxisomal thioesterases
(17). Both sequences end –AKL at their carboxy-terminal, which is a variant of
the peroxisomal consensus type 1 targeting signal of –SKL (PTS1) (25). A
catalytic triad containing serine (S), histidine (H), and aspartic acid (D)
residues, located at positions 232, 358 and 324 of PTE-Ic, has been identified in
this family of acyl-CoA thioesterases and is conserved also in these two
enzymes (26).
PTE-Ia and PTE-Ic are Localized in Peroxisomes- The nomenclature of PTE-Ia and
PTE-Ic were based on their putative consensus PTS1 of –AKL at their carboxy-
terminal ends. To test if these proteins are indeed peroxisomal, we cloned
both PTE-Ia and PTE-Ic in-frame with GFP, which leaves the carboxy-terminal
–AKL accessible. We transfected these plasmids into both control fibroblasts
and fibroblasts from a Zellweger patient, which are unable to import
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peroxisomal matrix proteins. Using immunofluorescence microscopy and a
Tritc-labeled secondary antibody to GFP, PTE-Ia showed a punctate pattern of
expression in control fibroblasts, indicative of a peroxisomal localization (Fig.
4A). However, in Zellweger fibroblasts, transfection of PTE-Ia resulted in a
diffuse GFP expression showing that PTE-Ia remained in the cytosol (Fig. 4B).
PTE-Ic also showed a punctate pattern of expression in control fibroblasts,
although some cytosolic staining was visible in this case (Fig 4C). Again, in
Zellweger fibroblasts, transfection of PTE-Ic resulted in a diffuse GFP
expression (Fig. 4D). Due to the 11 amino acid extension in the amino-
terminal of PTE-Ia (5’:1), we also examined the possibility of a mitochondrial
targeting of PTE-Ia. This was examined by expressing both the long (5’:1) and
the short (5’:2) amino-terminal variants of PTE-Ia as carboxy-terminal GFP
fusion proteins in fibroblasts. However the GFP experiments for these
variants showed only cytosolic labeling with no mitochondrial localization
(data not shown).
Recombinant Expression and Characterization- The cloning of the ORFs encoding
PTE-Ia (5’:1) and PTE-Ic into the Nde I site in the pET16b vector results in
expression of the proteins as His-tagged fusion proteins, which allows for
purification using affinity chromatography. Following purification on a Hi-
Trap‘ column, the purified proteins were detected as single bands of about
47 kDa on SDS-PAGE stained with Coomassie Brilliant blue (data not shown).
Following initial enzyme activity characterization of the recombinant protein,
it was evident that PTE-Ia activity, but not PTE-Ic activity, was inhibited with
substrates ranging from C14-C20 at concentrations higher than 5-10 mM.
However, addition of BSA to the reaction at an albumin/acyl-CoA ratio of
1:4.5 prevented inhibition (data not shown). Recombinant PTE-Ia and PTE-Ic
were analyzed for acyl-CoA thioesterase activity, which was determined at
several concentrations for a variety of acyl-CoA substrates, including
saturated and unsaturated straight-chain acyl-CoAs, branched-chain acyl-
CoAs and bile acid CoA-esters. Interestingly, in spite of the very high
sequence homology, PTE-Ia and PTE-Ic showed different chain-length
specificities for straight-chain acyl-CoAs. While PTE-Ia is a long-chain acyl-
CoA thioesterase (highest activity with palmitoyl-CoA, C16-CoA), PTE-Ic is a
medium-chain thioesterase (highest activity with decanoyl-CoA, C10-CoA)
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(Fig. 5). Neither of the enzymes was active on bile acid-CoA esters (tested
with choloyl-CoA and chenodeoxycholoyl-CoA). Vmax and Km values were
calculated for those acyl-CoAs that were substrates for PTE-Ia and PTE-Ic
(Table I). Further support for the difference in acyl-CoA chain-length
specificity stems from differences in the Km values. The Km values for PTE-Ia
were generally much lower for long-chain acyl-CoAs than those for PTE-Ic.
Also 4,8-dimethylnonanoyl-CoA (DMN-CoA), a metabolite in the b-oxidation
of pristanic acid, was found to be a better substrate for PTE-Ic than for PTE-Ia
(Table I).
We previously showed that mouse PTE-2, a peroxisomal acyl-CoA
thioesterase which hydrolyzes a variety of CoA esters, is strongly inhibited by
free CoASH (IC50≈10-15 m M) (19), suggesting that PTE-2 regulates
intraperoxisomal levels of free CoASH. We therefore tested the effect of
CoASH on the acyl-CoA thioesterase activity of PTE-Ia and PTE-Ic. However,
neither PTE-Ia nor PTE-Ic were markedly inhibited by CoASH when tested at
concentrations up to 500 mM, (data not shown), suggesting that PTE-Ia and
PTE-Ic are not involved in regulation of intra-peroxisomal CoASH levels, but
rather regulate intra-peroxisomal acyl-CoA levels.
Tissue Expression- The tissue expression of PTE-Ia and PTE-Ic at mRNA level
was examined using RT-PCR in several tissues, with b-actin as a control (Fig.
6A). PTE-Ia and PTE-Ic showed a selective tissue expression, with PTE-Ia
(both splice variants 5’:1 and 5’:2 amplified in the same PCR product) highly
expressed in kidney and only weakly expressed in the other tissues examined.
PTE-Ic is highly expressed in spleen, brain, testis and proximal and distal
intestine, and weakly expressed in the other tissues. Both PTE-Ia and PTE-Ic
are weakly expressed in liver from untreated mice, but strongly increased at
mRNA level by treatment of mice with WY-14,643 (Fig. 6A). A splice variant
of PTE-Ic identified as the lower band on the gel in Fig. 6A (marked with an
asterisk) was induced in liver by treatment with WY-14,643. Western blot
analysis for PTE-Ia (5’:1) on muscle, heart, lung, brown adipose tissue, brain,
liver and kidney showed no detectable protein expression in these tissues,
except for liver, with an induction seen in WY-14,643 treated liver. In kidney,
no immunoreactive protein was seen (Fig. 6B), but was detectable in fasted
kidney (where PTE-Ia 5’:1 may be strongly upregulated). As mentioned
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above, in one of the splice variants for PTE-Ia (5’:2), the nucleotides encoding
the first methionine is spliced out, producing a protein that is 11 amino acid
shorter and which lacks the epitope recognized by the PTE-Ia antibody.
Therefore the antibody recognizes only the PTE-Ia 5:1 splice variant. The lack
of immunoreactive protein in muscle, heart, lung, brown adipose tissue,
brain, and control kidney thus suggested that the PTE-Ia 5’:1 splice variant is
expressed only in liver, and that the high expression in kidney by RT-PCR
(Fig. 6A) represents the 5’:2 splice variant. To test this possibility, we PCR-
amplified the two splice variants in liver and kidney. As shown in Fig. 6C, the
PTE-Ia 5’:2 splice variant  is expressed in kidney, but not in liver. In contrast,
the PTE-Ia 5’:1 splice variant encoding the longer PTE-Ia protein containing
the antibody epitope could be PCR-amplified from liver, and this mRNA was
increased in response to WY-14,643 treatment (data not shown).
Regulation of PTE-Ia and PTE-Ic Expression by WY-14,643 Treatment and Fasting-
RT-PCR was carried out on total RNA from untreated and WY-14,643 treated
liver from wild-type (+/+) and PPARa-null (-/-) mice. Both PTE-Ia (splice
variants 5’:1 and 5’:2) and PTE-Ic were highly induced by WY-14,643
treatment in wild-type mice, but were not induced in the PPARa-null
animals, showing that this induction is mediated via PPARa (Fig. 7A, upper
panel). This induction was confirmed also at protein level by Western blot
analysis for PTE-Ia (Fig. 7A, lower panel) and by Northern blot analysis for
both PTE-Ia and PTE-Ic (data not shown). Northern blot analysis identified
two mRNA transcripts of approximately 2.2 kb and 2.8 kb for PTE-Ia, which
probably account for the difference in size of the two cDNA sequences for the
5’:1 and 5’:2 transcripts (approx. 750 bp). Regulation of both PTE-Ia and PTE-
Ic mRNA was also examined in liver, kidney and heart from mice fasted for
24 hours. RT-PCR showed that PTE-Ia was up-regulated by fasting in mouse
liver in wild-type animals, but not in the PPARa-null mice (Fig. 7B, upper
panel). This PPARa-dependent up-regulation by fasting was also confirmed
at protein level by Western blot analysis for PTE-Ia (Fig. 7B, lower panel).
As PTE-Ia (both splice variants 5’:1 and 5’:2) showed a very high expression in
kidney, we examined the regulation of the PTE-Ia in this organ during the
physiological condition of fasting. PTE-Ia mRNA expression was upregulated
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by fasting in mouse kidney in wild-type animals, and again this up-regulation
was abolished in the PPARa-null mice (Fig. 8). In contrast, expression of PTE-
Ic showed no regulation by fasting either in liver or kidney (Fig. 7B,upper
panel, Fig. 8), and neither PTE-Ia nor PTE-Ic was regulated by fasting in heart
(data not shown).
DISCUSSION
From previous work using molecular cloning and database mining, we have
now identified six highly homologous acyl-CoA thioesterase genes that are
located in a cluster on mouse chromosome 12, of which four genes encode
putative peroxisomal enzymes. These enzymes show approximately 40%
sequence identity to the bile acid-CoA:amino acid N-acyltransferase (BACAT)
(26), an enzyme involved in the conjugation of bile acids to glycine or taurine
(27-29). In addition, we have identified two further genes that are apparently
located close to the gene for BACAT on mouse chromosome 4. These two
genes also encode putative peroxisomal acyl-CoA thioesterases. This raised
the question as to why there are so many peroxisomal acyl-CoA thioesterases
in mouse. To address this issue, we have now cloned and characterized two of
these genes that we named PTE-Ia and PTE-Ic, and show that they are indeed
peroxisomal enzymes with different functions based on their different acyl-
CoA chain-length specificities and tissue expression. Elucidation of the
organization of the PTE-Ic gene shows that the open reading frame is encoded
by three exons, similar to the PTE-Ia and other Type-I genes (17). In this gene
family identified, the cytosolic (CTE-I) and the mitochondrial (MTE-I)
thioesterases show the highest degree of sequence identity to each other
(>90%), while the PTE-Ia and PTE–Ic are the most similar peroxisomal
thioesterases with a sequence identity of 82%. Most of the sequence
differences between all six thioesterases are found in the third exon, in the
area where the active-site catalytic triad is located, which indicates that these
thioesterases have different substrate specificities. Sequence analysis of PTE-
Ia and PTE–Ic shows that there are two regions within the third exon that are
less conserved, amino acids 257-280 of PTE-Ic (29% sequence identity) and
amino acids 369-384 (22% sequence identity). The enzyme activity
measurements showed that indeed these two enzymes have different
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substrate specificities, with PTE-Ia acting as a long-chain acyl-CoA
thioesterase, and PTE-Ic as a medium-chain acyl-CoA thioesterase.
Examination of tissue expression at mRNA level showed that these enzymes
have a different and very selective tissue expression, with PTE-Ia being highly
expressed in kidney and a lower expression in the rest of the tissues
examined, while PTE-Ic is highly expressed in spleen, brain, testis, proximal
and distal intestine and showed lower expression in the rest of the tissues.
The expression of both of these enzymes is highly up-regulated in liver by the
hypolipidemic drug WY-14,643 at both mRNA and protein level, and this
effect is mediated via PPARa. Although the highest PTE-Ia mRNA level was
found in kidney, surprisingly, there was no detectable protein in kidney from
untreated animals (Fig. 6B). In contrast, protein was readily detected in liver,
although the mRNA levels were much lower in liver than in kidney (Fig. 6A).
EST database searches suggested that the 5’-untranslated region of PTE-Ia
may be differently spliced, with one of the variants apparently splicing out
the first start methionine, resulting in a truncated protein lacking the first 11
amino acids (5’:2) (corresponding to most of the epitope against which the
PTE-Ia antibody was raised). Two EST sequences were found for this splice
variant 5’:2 (Accession numbers AW044864 and AI788456), both being
derived from mouse kidney. Our results now show that PTE-Ia 5’:2 is
expressed in kidney, but not in liver, while the longer PTE-Ia protein
(containing the extra 11 amino acids) appears to be more liver specific,
resulting in different tissue expression of these two proteins. As yet it is not
known what regulates the splicing within the different tissues, but the liver
specific expression of PTE-Ia (5’:1) may be regulated by liver-specific
transcription factors. The function of the 11 extra amino acids at the amino-
terminal of PTE-Ia is not clear. Sequence analysis did not indicate the
presence of an amino-terminal type-2 peroxisomal targeting signal (PTS-2)
which is present in some peroxisomal matrix proteins (30), nor the presence of
a mitochondrial targeting signal. This was verified experimentally by
expression of both the 5’:1 and 5’:2 PTE-Ia splice variants as carboxy-terminal
GFP fusion proteins in human skin fibroblasts. Both carboxy-terminal PTE-
Ia/GFP fusion proteins localized to the cytosol. In mammalian genomes, it
now appears that alternative splicing of many genes results in several
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different gene products (31), which may have different functions or show a
distinct tissue expression. Indeed, a splice variant for PTE-Ic was also detected
(marked with an asterisk), which splices out 118 bp of the open reading
frame, resulting in a premature stop codon, which should result in an inactive
protein that does not contain the active site histidine and aspartic acid
residues. The expression of this splice variant also shows tissue selectivity and
regulation by WY-14,643 (Fig. 6A and Fig. 7A).
Putative Functions for PTE-Ia and PTE-Ic in Peroxisomes:
The selective tissue expression and variation in regulation indicates different
functions for these two enzymes in peroxisomal lipid metabolism in different
organs. Peroxisomes have important functions in the degradation of a broad
spectrum of lipids, in particular lipids that are poorly metabolized by
mitochondria (for reviews, see (2,32,33). The main function of peroxisomal b-
oxidation is the metabolism of various carboxylic acids, for example
prostanoids and dicarboxylic fatty acids, into chain-shortened, more
hydrophilic compounds that can be excreted in the urine as free carboxylic
acids. Alternatively, peroxisomes chain-shorten long- and very long-chain
acyl-CoAs, which may then be transported to mitochondria for further
oxidation. The transport of fatty acids across the peroxisomal membrane is
not fully understood, but based on studies in mammalian cells and yeast it
appears that several mechanisms may operate in peroxisomes. Medium-chain
fatty acids may be transported across the peroxisomal membrane as free
acids, and become activated to the corresponding CoA-ester inside the
peroxisome (34). In contrast, long-chain fatty acids, trihydroxycoprostanoic
acid and prostanoids become activated outside the peroxisome, followed by
transport of the CoA-esters across the peroxisomal membrane (for reviews,
see (35,36). Since medium-chain fatty acids are transported into the
peroxisome, it is feasible to assume that they can also be transported out of
the peroxisome, for example in the case of chain-shortened fatty acids. It is
hypothesized that PTE-Ia and PTE-Ic may be involved in this process by
hydrolysis of long/medium-chain fatty acyl-CoA esters to the free fatty acid,
for transport out of the peroxisome to the mitochondria or endoplasmic
reticulum for further b- or w-oxidation. We also examined the activity of PTE-
Ia and PTE–Ic towards the b-oxidation intermediate 3-OH palmitoyl-CoA, but
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these enzymes had very low activity towards this compound, suggesting that
they can hydrolyze either the substrate or product of the b-oxidation pathway
in peroxisomes, but not intermediates in these pathways. The induction of
both PTE-Ia and PTE-Ic by both peroxisome proliferators and/or fasting in
liver and kidney is in line with an increase in b-oxidation activity in these
organs during conditions that increase oxidation capacity.
It has been established that long/medium chain fatty acids are transported to
mitochondria as the carnitine ester for complete b-oxidation. Peroxisomes
contain a carnitine octanoyltransferase that can potentially convert medium-
chain acyl-CoAs to the corresponding carnitine ester for transport to
mitochondria. The physiological role of this carnitine octanoyltransferase is
not fully clear, but it was shown that this enzyme converts 4,8-
dimethylnonanoyl-CoA, a metabolite of pristanic acid, to its corresponding
carnitine ester, which is required for its transport to mitochondria for further
b-oxidation (37). In contrast, essentially no information is available concerning
transport of free CoASH across the peroxisomal membrane. Two important
functions can therefore be proposed for acyl-CoA thioesterases in
peroxisomes (i) to terminate chain-shortening of various carboxylic acids to
promote transport out of the peroxisome for transport to mitochondria for
further oxidation (short-, medium- and long-chain fatty acids), or for secretion
into urine (dicarboxylic fatty acids and chain-shortened prostanoids), and (ii)
to regulate intra-peroxisomal levels of acyl-CoA/CoASH.
In mouse six different Type I acyl-CoA thioesterases have been identified, one
cytosolic, one mitochondrial and four peroxisomal acyl-CoA thioesterases
(PTE-Ia-d) ((17), this study and unpublished data). In addition, peroxisomes
contain another structurally unrelated acyl-CoA thioesterase, called PTE-2.
This enzyme was initially identified as a HIV-1 Nef binding protein (21,22),
and subsequently further characterized as an acyl-CoA thioesterase in mouse,
human, yeast and rat (19,20,23,38). Characterization of PTE-2 in mouse
showed it to be the major acyl-CoA thioesterase in peroxisomes, hydrolyzing
a broad range of acyl-CoA esters.  The activity of recombinant PTE-2 is
strongly regulated by CoASH (IC50≈10 mM), suggesting that PTE-2 regulates
intra-peroxisomal CoA-levels (19). Comparison of the acyl-CoA thioesterase
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activity in isolated peroxisomes with recombinant PTE-2 suggests that this
enzyme is responsible for essentially all thioesterase activity except for the
activity on medium- to long-chain acyl-CoAs which is induced in rat liver
peroxisomes by peroxisome proliferator treatment (16). The findings reported
in this study that PTE-Ia and PTE-Ic are peroxisome proliferator-induced
long- and medium-chain acyl-CoA thioesterases therefore provides data to
show that in principle PTE-2, PTE-Ia and PTE-Ic are responsible for the
peroxisomal acyl-CoA thioesterase covering C2-C22 acyl-CoAs. It is therefore
likely that the remaining uncharacterized peroxisomal acyl-CoA thioesterases
have activities towards other more specific substrates. Experiments are
presently underway in our laboratory to examine this.
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TABLE I
Calculated Vmax and Km values for recombinant PTE-Ia and PTE-Ic
Acyl-CoA thioesterase activity for PTE-Ia and PTE-Ic was measured with
different acyl-CoA substrates at various concentrations. Vmax and Km was
calculated using Sigma Plot Enzyme Kinetics program. Activities were
measured on three different recombinant protein preparations for PTE-Ia and
on two different recombinant protein preparations for PTE-Ic. Results from
one representative experiment are shown. DMN: dimethylnonanoyl-CoA.
ND: not detectable.
                PTE-Ia                 PTE-Ic
Acyl-CoAs Vmax Km Vmax Km
! (µmol/min/mg) (µM) (µmol/min/mg) (µM)
Hexanoyl 0.02 10.9 0.23 28.4
Octanoyl 0.23 46.2 0.74 7.7
Decanoyl 0.87 7.7 1.20 18
Lauroyl 1.40 7.6 1.10 7.6
Myristoyl 1.60 3.8 0.83 5.6
Palmitoyl 1.85 4.0 0.49 15.9
Palmitoleoyl 0.93 2.8 0.32 7.0
Stearoyl 1.43 4.2 0.38 34.8
Oleoyl 0.85 4.6 0.14 8.9
Linoleoyl 0.63 2.6 0.17 32.5
Arachidoyl 0.71 2.2 0.18 32.7
Arachidonoyl 0.70 7.2 0.23 1.6
Behenoyl 0.37 2.3 ND! ND
Lignoceroyl 0.20 6.3 ND! ND
Cerotoyl 0.22 4.5              ND   ND!
DMN 0.32 16.9 0.81 32.3
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Figure legends
Fig. 1. Genomic localization of PTE-Ia and PTE-Ic. The Type-I acyl-CoA
thioesterase gene cluster consists of six genes encoding one mitochondrial
acyl-CoA thioesterase (MTE-I), one cytosolic acyl-CoA thioesterase (CTE-I)
and four putative peroxisomal acyl-CoA thioesterases (PTE-Ia/b/c/d), which
are localized within 120-kb on chromosome 12 in mouse.
Fig. 2. Structural organization of the PTE-Ia and PTE-Ic genes. (A) The open
reading frame for both PTE-Ia and PTE–Ic is encoded by three exons (boxes),
spaced by two introns (broken lines). EST database searches identified two 5’-
variants of the PTE-Ia, which are denoted 5’:1 and 5’:2, and contain a short
exon encoding a further 5’ untranslated region. The 5’:1 splice variant
contains the first in-frame ATG, encoding an 11 amino-acid longer PTE-Ia. In
the 5’:2 splice variant, the first ATG is spliced out, encoding a PTE-Ia protein
which is 11 amino acids shorter. TGA: stop codon (B) Sequence alignment
and comparison of the 5’:1 and 5’:2 splice variants. Nucleotides of the open
reading frame are shown in capital letters, with the ATG codons underlined.
Splice donor and acceptor sites are shown in italics. In 5’:1, 547 bp are spliced
out, and in 5’:2 1293 bp are spliced out. In the sequence corresponding to 5’:1,
719 bp (-719) were omitted to allow sequence comparison to 5’:2.
Fig. 3. Sequence alignment of PTE-Ia and PTE-Ic. Alignment of the amino
acid sequences of PTE-Ia and PTE-Ic was performed using the Clustal X
method. PTE-Ia 5’:1 commences at the first methoinine, while 5’:2 commences
at the second methionine. Individual exon boundaries are indicated. The
catalytic triad consisting of a serine (corresponding to serine 232 in the PTE-
Ic), a histidine (358) and an aspartic acid (324) residue is indicated with
arrowheads. Both enzymes contain a carboxy-terminal peroxisomal type 1
targeting signal of –AKL.
Fig. 4. PTE-Ia and PTE-Ic are peroxisomal proteins. Human skin fibroblasts
were transfected with PTE-Ia/NT-GFP or PTE-Ic/NT-GFP and processed for
immunofluorescence microscopy as outlined in Experimental Procedures. The
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cellular localization of PTE-Ia and PTE-Ic was examined in control fibroblasts
or Zellweger fibroblasts using a Tritc-labeled anti-GFP antibody: (A) PTE-Ia in
control fibroblasts (B) PTE-Ia in Zellweger fibroblasts (C) PTE-Ic in control
fibroblasts (D) PTE-Ic in Zellweger fibroblasts.
Fig. 5. Kinetic characterization of recombinant PTE-Ia and PTE-Ic.
Recombinant PTE-Ia and PTE-Ic were expressed in Escherichia coli as His-
tagged proteins and purified by affinity chromatography as described in
Experimental Procedures. Acyl-CoA thioesterase activity was measured at 25
mM substrate concentration, with the addition of bovine serum albumin at a
molar ratio of 1:4.5 of BSA:acyl-CoA for C14-C20-CoAs in the case of PTE-Ia.
The figure shows data from one representative experiment. The activity
measurements were carried out on three different recombinant protein
preparations for PTE-Ia and on two different recombinant protein
preparations for PTE-Ic.
Fig. 6. Tissue expression of PTE-Ia and PTE-Ic. (A) The tissue expression of
PTE-Ia (both 5’:1 and 5’:2 splice variants amplified) and PTE-Ic was examined
using RT-PCR, with b-actin as a control. The PTE-Ic splice variant is indicated
with an asterisk * (B) Western blot analysis was carried out on 50 mg of
protein from each tissue, using an anti-PTE-Ia antibody as described in
Experimental Procedures. (C) RT-PCR from mouse liver and kidney using
primers to amplify the PTE-Ia 5’:2 variant. The negative control (NC)
contained no RNA. MM: molecular marker.
Fig. 7. Regulation of PTE-Ia and PTE-Ic in mouse liver by WY-14,643
treatment and fasting. (A) Wild-type (+/+) or PPARa-null (-/-) mice were
treated with 0.1% WY-14,643 for one week. The mRNA levels of PTE-Ia (both
5’:1 and 5’:2 splice variants amplified) and PTE-Ic were examined in mouse
liver using RT-PCR, with b-actin as a control (upper panel). The PTE-Ic splice
variant is indicated with an asterisk *. Western blot analysis was carried out
on 50 mg liver protein from two wild-type (+/+) and PPARa-null (-/-) mice
treated with 0.1% WY-14,643 for one week, using an anti-PTE-Ia antibody as
described in Experimental Procedures (lower panel). (B) Wild-type (+/+) or
PPARa-null (-/-) mice were fasted for 24 hours. The mRNA levels of PTE-Ia
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(both 5’:1 and 5’:2 splice variants amplified) and PTE-Ic were examined in
liver using RT-PCR, with b-actin as a control. In all cases, the negative control
(NC) contained no RNA. MM, molecular marker (upper panel). Western blot
analysis was carried out on 50 mg of liver protein from two wild-type (+/+)
and two PPARa-null (-/-) mice fasted for 24 hours, using an anti-PTE-Ia
antibody as described in Experimental Procedures (lower panel).
Fig. 8: Regulation of PTE-Ia and PTE-Ic by fasting in kidney. Wild-type
(+/+) or PPARa-null (-/-) mice were fasted for 24 hours. The mRNA levels of
PTE-Ia and PTE-Ic were examined in kidney using RT-PCR, with b-actin as a
control. The negative control (NC) contained no RNA. MM, molecular
marker.
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B
M H A F T T Q N P N R M A P T V I L E P A G G C L C D Q P V H I A V R G L A P E 40mPTE-Ia
- - - - - - - - - - - M V P T V S L E P T G H S C W D E P L S I A V R G L A P E 29mPTE-Ic
Q P V T L R S V L R D E K G A L F R A H A R Y R A D S H G E L D L A R T P A L G 80mPTE-Ia
Q P V T L R T A L R D E K G A L F R A H A R Y R A D S H G E L D L A R T P A L G 69mPTE-Ic
G S F S G L E P M G L L W A M E P D R P F W R L I K R D V Q T P F V V E L E V L 120mPTE-Ia
G S F S G L E P M G L L W A M E P D R P F W R L I K R D V Q T P F V V E L E V L 109mPTE-Ic
D G H E P D G G Q R L A R A V H E R H F M A P G V R R V P V R E G R V R A T L F 160mPTE-Ia
D G H E P D G G R L L A R A V H E R H F M A P G V R R V P V R E G R V R A T L F 149mPTE-Ic
L P P G T G P F P G I I D L F G I G S G L L E Y R A S L L A G K G F A V M A L A 200mPTE-Ia
L P P G T G P F P G I I D L F G V G G G L L E Y R A S L L A G K G F A V M A L A 189mPTE-Ic
Y N N Y E D L P K D M D I I H L E Y F E E A V T Y L L S H P Q V T G S G V G V L 240mPTE-Ia
Y Y K Y D D L P K V I D I L H L E Y F E E A V T Y L L S H P Q V K G P G V G L L 229mPTE-Ic
G I S K G G E L G F A M A S F L K N I T A A V I I N G S I S N I G G N L Q Y K D 280mPTE-Ia
G I S K G A E L S L S M A S F L K G I T A A V V I N G A T V N V I S T L Y Y K E 269mPTE-Ic
E T V P S V G I N T K R V K R T K D G L K D I V D L L N N P L E G P D Q K S L I 320mPTE-Ia
E S L P G L G M H L E R I K V T K D G F K D I I D I L N V P L E A P D Q K S L I 309mPTE-Ic
P V E R S D T A F L F L V G Q D D H N W K S E F Y A R E A S K R L Q A H G K E K 360mPTE-Ia
P L E R S D T A F L F L V G Q D D H N W K S E F Y A R E A S K R L Q A H G K E K 349mPTE-Ic
P Q I I C Y P E T G H H I E P P Y F P L C K A S L N S L V G G P V I W G G E P R 400mPTE-Ia
P Q I V C Y P K T G H H I E P P Y I P W S I A A P H S Y F D K P I L L G G E P R 389mPTE-Ic
A H A M A Q V D A W Q Q L Q T F F H N H L D G K K K T I P A K L                 432mPTE-Ia
A H A M A Q V D A W Q R L Q T F F H K H L S G D K R P S P A K L                 421mPTE-Ic
Decoration '': Shade (with solid black) residues that match mPTE-Ia exactly.
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